Autor: "Vermeire, Severine" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use
Autorzy :: HAZES, Johanna M. W
COULIE, Pierre G
GEENEN, Vincent
VERMEIRE, Severine
CARBONNEL, Franck
LOUIS, Edouard
MASSON, Pierre
DE KEYSER, Filip; Pokaż więcej
Temat :: Immunopathologie
Immunopathology
Inmunopatología
Maladie autoimmune
Autoimmune disease
Enfermedad autoinmune
Pathologie du système ostéoarticulaire
Diseases of the osteoarticular system
Sistema osteoarticular patología
Rhumatisme inflammatoire
Inflammatory joint disease
Reumatismo inflamatorio
Traitement
Treatment
Tratamiento
Anti-TNF
Article synthèse
Review
Artículo síntesis
Chimiothérapie
Chemotherapy
Quimioterapia
Chronique
Chronic
Crónico
Evolution
Evolución
Gestation
Pregnancy
Gestación
Homme
Human
Hombre
Polyarthrite rhumatoïde
Rheumatoid arthritis
Poliartritis reumatoidea
Pronostic
Prognosis
Pronóstico
Revue bibliographique
Bibliographic review
Revista bibliográfica
Rhumatologie
Rheumatology
Reumatología
Toxicomanie
Drug addiction
Toxicomanía
Indice d'activité
Activity index
Disease activity
Drug treatment
Pregnancy outcome
Sciences biologiques et medicales
Biological and medical sciences
Sciences medicales
Medical sciences
Toxicologie
Toxicology
Toxicomanies
Drug addictions
Pathologie osteoarticulaire
Inflammatory joint diseases
Psychopathologie. Psychiatrie
Psychopathology. Psychiatry
Etude clinique de l'adulte et de l'adolescent
Adult and adolescent clinical studies
Conduites addictives
Addictive behaviors
Psychologie. Psychanalyse. Psychiatrie
Psychology. Psychoanalysis. Psychiatry
PSYCHOPATHOLOGIE. PSYCHIATRIE
Źródło :: Rheumatology (Oxford. Print). 50(11):1955-1968
Materiał oryginalny :: INIST-CNRS
Opis pliku :: text
Dostęp URL :: http://pascal-francis.inist.fr/vibad/index.php?action=search&terms=24740582
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Variability in the Distribution of Histological Disease Activity in the Colon of Patients with Ulcerative Colitis.
Autorzy :: Bossuyt P; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
Bisschops R; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
De Hertogh G; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Apr 06; Vol. 15 (4), pp. 603-608.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases.
Autorzy :: Liefferinckx C; Department of Gastroenterology, Hôpital Erasme, ULB, Brussels, Belgium.
Bottieau J; Department of Electrical Engineering, University of Mons, Mons, Belgium.
Toubeau JF; Department of Electrical Engineering, University of Mons, Mons, Belgium.
Thomas D; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Rahier JF; Department of Gastroenterology, CHU UCL Namur, Yvoir, Belgium.
Louis E; Department of Gastroenterology, Centre Hospitalier Universitaire Sart-Tilman, ULG, Liège, Belgium.
Baert F; Department of Gastroenterology, AZ Delta, Roeselare-Menen-Torhout, Belgium.
Dewint P; Department of Gastroenterology, AZ Maria Middelares, Ghent, Belgium.; Department of Gastroenterology, UZ Antwerp, Antwerp, Belgium.
Pouillon L; Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
Lambrecht G; Department of Gastroenterology, AZ Damiaan, Oostende, Belgium.
Vallée F; Department of Electrical Engineering, University of Mons, Mons, Belgium.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Bossuyt P; Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
Franchimont D; Department of Gastroenterology, Hôpital Erasme, ULB, Brussels, Belgium.; Pokaż więcej
Źródło :: Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon.
Autorzy :: Verstockt B; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.
Verstockt S; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.
Abdu Rahiman S; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.
Ke BJ; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.
Arnauts K; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.; Department of Development and Regeneration, Stem Cell Institute Leuven [SCIL], KU Leuven, Leuven, Belgium.
Cleynen I; Department of Human Genetics, Laboratory for Complex Genetics, KU Leuven, Leuven, Belgium.
Sabino J; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.
Matteoli G; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], Translational Research Center for Gastrointestinal Disorders [TARGID], KU Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Mar 05; Vol. 15 (3), pp. 485-498.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
Autorzy :: Verstockt S; Translational Research Center for GastroIntestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium.
Verstockt B; Translational Research Center for GastroIntestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
Machiels K; Translational Research Center for GastroIntestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium.
Vancamelbeke M; Translational Research Center for GastroIntestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium.
Ferrante M; Translational Research Center for GastroIntestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
Cleynen I; Laboratory for Complex Genetics, Department of Human Genetics, Leuven, Belgium.
De Hertogh G; Department of Morphology and Molecular Pathology, University Hospitals, Leuven, Belgium.; Department of Imaging and Pathology, Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.
Vermeire S; Translational Research Center for GastroIntestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.; Pokaż więcej
Źródło :: Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Feb 24. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: the open-label study TURANDOT II.
Autorzy :: Reinisch W; Medical University of Vienna, Vienna, Austria.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.
Danese S; Humanitas University, Milan, Italy.
Hébuterne X; University of Nice Sophia Antipolis, CHU of Nice, Nice, France.
Kłopocka M; Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
Tarabar D; Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia.
Vaňásek T; Charles University Hospital, Hradec Králové, Czech Republic.
Greguš M; Gastroenterology Centre, Nitra, Slovakia.
Hellstern PA; Nature Coast Clinical Research, Inverness, FL, USA.
Kim JS; Seoul National University College of Medicine, Seoul, South Korea.
Sparrow MP; Alfred Hospital, Melbourne, VIC, Australia.
Gorelick KJ; Zymo Consulting Group, Newtown Square, PA, USA.
Hoy M; Shire, a Takeda company, Lexington, MA, USA.
Goetsch M; Shire, a Takeda company, Zug, Switzerland.
Bliss C; Shire, a Takeda company, Lexington, MA, USA.
Gupta C; Cytel Inc, Cambridge, MA, USA.
Cataldi F; Shire, a Takeda company, Lexington, MA, USA.
Vermeire S; University Hospitals Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Feb 18. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
Autorzy :: Vermeire S; Department of Gastroenterology & Hepatology, University Hospitals Leuven, Leuven, Belgium.
Chiorean M; Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA, USA.
Panés J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Peyrin-Biroulet L; Department of Gastroenterology, Nancy University Hospital, Nancy, France, and INSERM U1256 NGERE, Lorraine University, Nancy, France.
Zhang J; Arena Pharmaceuticals, Inc., San Diego, CA, USA.
Sands BE; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lazin K; Arena Pharmaceuticals, Zug, Switzerland.
Klassen P; Arena Pharmaceuticals, Inc., San Diego, CA, USA.
Naik SU; Arena Pharmaceuticals, Inc., San Diego, CA, USA.
Cabell CH; Arena Pharmaceuticals, Inc., San Diego, CA, USA.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Jan 21. Date of Electronic Publication: 2021 Jan 21.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study.
Autorzy :: Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Western University, London, Ontario, Canada.
Hanauer S; Feinberg School of Medicine, Chicago, IL, USA.
Vermeire S; University of Leuven, Leuven, Belgium.
Ghosh S; University of Calgary, Alberta, Canada.
Liu WJ; Bristol-Myers Squibb, Princeton, NJ, USA.
Petersen A; Bristol-Myers Squibb, Princeton, NJ, USA.
Charles L; Bristol-Myers Squibb, Princeton, NJ, USA.
Huang V; Bristol-Myers Squibb, Princeton, NJ, USA.
Usiskin K; Bristol-Myers Squibb, Princeton, NJ, USA.
Wolf DC; Center for Crohn's Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, USA.
D'Haens G; Inflammatory Bowel Disease Center, Amsterdam University Medical Center, Amsterdam, the Netherlands.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Jan 13. Date of Electronic Publication: 2021 Jan 13.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: The Role of Citrullination in Inflammatory Bowel Disease: A Neglected Player in Triggering Inflammation and Fibrosis?
Autorzy :: Dragoni G; KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders, Leuven, Belgium.; Gastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Florence, Italy.; Department of Medical Biotechnologies, University of Siena, Italy.
De Hertogh G; KU Leuven, Department of Imaging and Pathology, Translational Cell & Tissue Research, Leuven, Belgium.
Vermeire S; KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Jan 01; Vol. 27 (1), pp. 134-144.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis.
Autorzy :: Sudhakar P; Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID).
Verstockt B; Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID).; University Hospitals Leuven, Department of Gastroenterology and Hepatology.
Cremer J; Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Katholieke Universiteit Leuven, Leuven, Belgium.
Verstockt S; Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID).
Sabino J; Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID).; University Hospitals Leuven, Department of Gastroenterology and Hepatology.
Ferrante M; Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID).; University Hospitals Leuven, Department of Gastroenterology and Hepatology.
Vermeire S; Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID).; University Hospitals Leuven, Department of Gastroenterology and Hepatology.; Pokaż więcej
Źródło :: Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Dec 14. Date of Electronic Publication: 2020 Dec 14.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomized RIVETING Trial.
Autorzy :: Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Su C; Pfizer Inc, Collegeville, Pennsylvania, United States.
Lawendy N; Pfizer Inc, Collegeville, Pennsylvania, United States.
Kobayashi T; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California, United States.
Rubin DT; University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, Illinois, United States.
Modesto I; Pfizer Inc, New York, New York, United States.
Gardiner S; Pfizer Inc, New York, New York, United States.
Kulisek N; Pfizer Inc, Collegeville, Pennsylvania, United States.
Zhang H; Pfizer Inc, Collegeville, Pennsylvania, United States.
Wang W; Pfizer Inc, Collegeville, Pennsylvania, United States.
Panés J; Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Dec 08. Date of Electronic Publication: 2020 Dec 08.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations.
Autorzy :: Van den Berghe N; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Verstockt B; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Gils A; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Sabino J; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Declerck P; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Thomas D; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Nov 27. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Early Postoperative Endoscopic Recurrence in Crohn's Disease Is Characterised by Distinct Microbiota Recolonisation.
Autorzy :: Machiels K; Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.
Pozuelo Del Río M; Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.
Martinez-De la Torre A; Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.
Xie Z; Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.
Pascal Andreu V; Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.
Sabino J; Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Santiago A; Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.
Campos D; Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.
Wolthuis A; Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium.
D'Hoore A; Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium.
De Hertogh G; Department of Imaging & Pathology, KU Leuven, Leuven, Belgium.
Ferrante M; Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Manichanh C; Department of Gastroenterology, Vall d'Hebron Research Institute, Barcelona, Spain.; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Vermeire S; Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Nov 07; Vol. 14 (11), pp. 1535-1546.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Autorzy :: Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Lukáš M; IBD Clinical and Research Centre, ISCARE Clinical Centre, Prague, Czech Republic.
Magro F; Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal.
Adsul S; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Lindner D; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Rosario M; Takeda Development Center Americas Inc., Cambridge, MA, USA.
Roth J; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Danese S; Department of Gastroenterology, IBD Center, Humanitas Research Hospital, Rozzano, Italy.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Sep 07; Vol. 14 (8), pp. 1066-1073.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: JAK Inhibitors: Back to Small Molecules for the Treatment of IBD.
Autorzy :: Panés J; Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Vermeire S; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Aug 01; Vol. 14 (Supplement_2), pp. S711-S712.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Neutrophilic HGF-MET signaling exacerbates intestinal inflammation.
Autorzy :: Stakenborg M; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
Verstockt B; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.
Meroni E; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
Goverse G; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
De Simone V; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
Verstockt S; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
Di Matteo M; Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, 3000 Leuven, Belgium.; Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, Center for Cancer Biology, KU Leuven, 3000 Leuven, Belgium.
Czarnewski P; Department of Medicine, Immunology and Allergy division, Karolinska Institutet and Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Villablanca EJ; Department of Medicine, Immunology and Allergy division, Karolinska Institutet and Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
Ferrante M; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.
Boeckxstaens GE; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
Mazzone M; Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, 3000 Leuven, Belgium.; Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, Center for Cancer Biology, KU Leuven, 3000 Leuven, Belgium.
Vermeire S; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.
Matteoli G; Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Jun 17. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
Autorzy :: Verstockt B; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.; KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium.
Mertens E; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
Dreesen E; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies.
Outtier A; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
Noman M; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
Tops S; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies.
Schops G; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
Van Assche G; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.; KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium.
Vermeire S; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.; KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium.
Gils A; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies.
Ferrante M; University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.; KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Mar 13; Vol. 14 (3), pp. 332-341.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/immunology
Endoscopy, Digestive System*/methods
Endoscopy, Digestive System*/statistics & numerical data
Tumor Necrosis Factor Inhibitors*/administration & dosage
Tumor Necrosis Factor Inhibitors*/immunology
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Adult ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/physiopathology ; Crohn Disease/diagnosis ; Crohn Disease/physiopathology ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/immunology ; Humans ; Male ; Medication Therapy Management ; Middle Aged ; Needs Assessment ; Outcome Assessment, Health Care/methods ; Prognosis ; Remission Induction/methods ; Tertiary Care Centers/statistics & numerical data ; Treatment Outcome
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 18 18.

Tytuł :: Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
Autorzy :: Bronswijk M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Moens A; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Aging, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
Lenfant M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Tops S; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Compernolle G; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Van Assche G; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Aging, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Aging, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
Gils A; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.; Translational Research in GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Aging, and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Mar 04; Vol. 26 (4), pp. 628-634.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*therapeutic use
Biosimilar Pharmaceuticals/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Infliximab/*therapeutic use
Adult ; Antibodies, Monoclonal/adverse effects ; Biosimilar Pharmaceuticals/adverse effects ; Colitis, Ulcerative/blood ; Crohn Disease/blood ; Female ; Humans ; Infliximab/blood ; Infliximab/pharmacokinetics ; Male ; Middle Aged ; Patient Reported Outcome Measures ; Prospective Studies ; Remission Induction ; Tertiary Care Centers
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
Autorzy :: Dreesen E; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Kantasiripitak W; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Detrez I; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Stefanović S; Department of Gastroenterology and Hepatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Bouillon T; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Drobne D; Department of Gastroenterology and Hepatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Gils A; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.; Pokaż więcej
Źródło :: Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Mar 04; Vol. 26 (4), pp. 570-580.
Typ publikacji :: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*therapeutic use
Colitis, Ulcerative/*drug therapy
Tumor Necrosis Factor Inhibitors/*therapeutic use
Adult ; Antibodies, Monoclonal/pharmacokinetics ; Colitis, Ulcerative/pathology ; Drug Monitoring ; Endoscopy ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; ROC Curve ; Regression Analysis ; Remission Induction ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/pharmacokinetics ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
Autorzy :: de Bruyn M; Translational Research Centre for GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium.; Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Ringold R; Kepler Diagnostics, Inc., Simi Valley, California, USA.
Martens E; Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Ferrante M; Translational Research Centre for GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
Van Assche G; Translational Research Centre for GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
Opdenakker G; Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Dukler A; Kepler Diagnostics, Inc., Simi Valley, California, USA.
Vermeire S; Translational Research Centre for GastroIntestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.; Pokaż więcej
Źródło :: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Feb 10; Vol. 14 (2), pp. 176-184.
Typ publikacji :: Journal Article
MeSH Terms :: Adalimumab/*therapeutic use
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Intestinal Mucosa/*pathology
Adult ; Antimicrobial Cationic Peptides/blood ; Biomarkers/blood ; Case-Control Studies ; Chitinase-3-Like Protein 1/blood ; Colitis, Ulcerative/pathology ; Female ; Humans ; Intestinal Mucosa/drug effects ; Leukocyte Count ; Lipocalin-2/blood ; Male ; Matrix Metalloproteinase 9/blood ; Middle Aged ; Neutrophils ; ROC Curve ; Receptors, Tumor Necrosis Factor/antagonists & inhibitors ; Remission Induction
: Czasopismo naukowe

Szczegóły Pełny tekst

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Vermeire, Severine"" wg kryterium: Autor

Aktywne filtry:

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Publikacja

Język